Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients. 2009

Rey-Yue Yuan, and Jau-Jiuan Sheu, and Jia-Ming Yu, and Chaur-Jong Hu, and Ing-Jy Tseng, and Chun-Sum Ho, and Ching-Ying Yeh, and Ya-Lin Hung, and Tsuey-Ru Chiang
Department of Neurology, Taipei Medical University Hospital, Taipei, Taiwan.

Genetic C677T and A1298C polymorphisms in 5,10-methylenetetrahydrofolate reductase (MTHFR) and levodopa therapy in Parkinson's disease (PD) may increase homocysteine (Hcy) level. We examined whether connecting both polymorphisms influences the effect of levodopa on Hcy. MTHFR genotypes and Hcy, vitamin B(12), and folate levels were determined in 48 levodopa-treated PD patients (PD-L), 28 non-treated PD patients (PD-N) and 110 controls. Hcy was remarkably higher in PD-L than in PD-N and controls (p<0.001); similarly, the differences were seen in different age subgroups and in both genders. Furthermore, Hcy differences between PD-L and PD-N were evident in 677C/T, T/T, C/T + A/A, T/T + A/A (all p<0.05), and 1298A/A (p<0.001), but not in others such as 677C/C, and C/C + A/A. Hcy in PD-N and controls was comparable for all genotypes. In PD-L, Hcy was the highest in 677T/T, then in C/T, and in C/C with a significant difference from T/T (p=0.014), but was not different among A1298C genotypes. Likewise, Hcy was the highest in 677T/T+1298A/A, intermediate in C/T+A/A, and the lowest in C/C+A/A. In PD-N, Hcy was similar among all genotypes. In conclusion, Hcy elevation may be caused by levodopa administration, and further promoted by 677C/T and T/T, but not by A1298C genotypes. The promoting elevation in 1298A/A is attributed to combining the 677T allele. Neither C677T nor A1298C genotypes contribute to elevating Hcy in PD-N.

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D004252 DNA Mutational Analysis Biochemical identification of mutational changes in a nucleotide sequence. Mutational Analysis, DNA,Analysis, DNA Mutational,Analyses, DNA Mutational,DNA Mutational Analyses,Mutational Analyses, DNA
D005260 Female Females
D005787 Gene Frequency The proportion of one particular in the total of all ALLELES for one genetic locus in a breeding POPULATION. Allele Frequency,Genetic Equilibrium,Equilibrium, Genetic,Allele Frequencies,Frequencies, Allele,Frequencies, Gene,Frequency, Allele,Frequency, Gene,Gene Frequencies
D005819 Genetic Markers A phenotypically recognizable genetic trait which can be used to identify a genetic locus, a linkage group, or a recombination event. Chromosome Markers,DNA Markers,Markers, DNA,Markers, Genetic,Genetic Marker,Marker, Genetic,Chromosome Marker,DNA Marker,Marker, Chromosome,Marker, DNA,Markers, Chromosome
D005820 Genetic Testing Detection of a MUTATION; GENOTYPE; KARYOTYPE; or specific ALLELES associated with genetic traits, heritable diseases, or predisposition to a disease, or that may lead to the disease in descendants. It includes prenatal genetic testing. Genetic Predisposition Testing,Genetic Screening,Predictive Genetic Testing,Predictive Testing, Genetic,Testing, Genetic Predisposition,Genetic Predictive Testing,Genetic Screenings,Genetic Testing, Predictive,Predisposition Testing, Genetic,Screening, Genetic,Screenings, Genetic,Testing, Genetic,Testing, Genetic Predictive,Testing, Predictive Genetic
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes

Related Publications

Rey-Yue Yuan, and Jau-Jiuan Sheu, and Jia-Ming Yu, and Chaur-Jong Hu, and Ing-Jy Tseng, and Chun-Sum Ho, and Ching-Ying Yeh, and Ya-Lin Hung, and Tsuey-Ru Chiang
May 2023, Brain and behavior,
Rey-Yue Yuan, and Jau-Jiuan Sheu, and Jia-Ming Yu, and Chaur-Jong Hu, and Ing-Jy Tseng, and Chun-Sum Ho, and Ching-Ying Yeh, and Ya-Lin Hung, and Tsuey-Ru Chiang
December 1999, European journal of clinical investigation,
Rey-Yue Yuan, and Jau-Jiuan Sheu, and Jia-Ming Yu, and Chaur-Jong Hu, and Ing-Jy Tseng, and Chun-Sum Ho, and Ching-Ying Yeh, and Ya-Lin Hung, and Tsuey-Ru Chiang
December 2012, Zhonghua xin xue guan bing za zhi,
Rey-Yue Yuan, and Jau-Jiuan Sheu, and Jia-Ming Yu, and Chaur-Jong Hu, and Ing-Jy Tseng, and Chun-Sum Ho, and Ching-Ying Yeh, and Ya-Lin Hung, and Tsuey-Ru Chiang
August 2002, Zhonghua nei ke za zhi,
Rey-Yue Yuan, and Jau-Jiuan Sheu, and Jia-Ming Yu, and Chaur-Jong Hu, and Ing-Jy Tseng, and Chun-Sum Ho, and Ching-Ying Yeh, and Ya-Lin Hung, and Tsuey-Ru Chiang
February 2013, Zhonghua yi xue za zhi,
Rey-Yue Yuan, and Jau-Jiuan Sheu, and Jia-Ming Yu, and Chaur-Jong Hu, and Ing-Jy Tseng, and Chun-Sum Ho, and Ching-Ying Yeh, and Ya-Lin Hung, and Tsuey-Ru Chiang
January 2005, Movement disorders : official journal of the Movement Disorder Society,
Rey-Yue Yuan, and Jau-Jiuan Sheu, and Jia-Ming Yu, and Chaur-Jong Hu, and Ing-Jy Tseng, and Chun-Sum Ho, and Ching-Ying Yeh, and Ya-Lin Hung, and Tsuey-Ru Chiang
December 2005, Annals of neurology,
Rey-Yue Yuan, and Jau-Jiuan Sheu, and Jia-Ming Yu, and Chaur-Jong Hu, and Ing-Jy Tseng, and Chun-Sum Ho, and Ching-Ying Yeh, and Ya-Lin Hung, and Tsuey-Ru Chiang
December 2022, The International journal of neuroscience,
Rey-Yue Yuan, and Jau-Jiuan Sheu, and Jia-Ming Yu, and Chaur-Jong Hu, and Ing-Jy Tseng, and Chun-Sum Ho, and Ching-Ying Yeh, and Ya-Lin Hung, and Tsuey-Ru Chiang
February 2009, Journal of thrombosis and thrombolysis,
Rey-Yue Yuan, and Jau-Jiuan Sheu, and Jia-Ming Yu, and Chaur-Jong Hu, and Ing-Jy Tseng, and Chun-Sum Ho, and Ching-Ying Yeh, and Ya-Lin Hung, and Tsuey-Ru Chiang
September 2013, Gene,
Copied contents to your clipboard!